Literature DB >> 19406069

Molecular basis of leukocyte-endothelium interactions during the inflammatory response.

Olga Barreiro1, Francisco Sánchez-Madrid.   

Abstract

The process of leukocyte extravasation, a critical step in the inflammatory response, involves the migration of leukocytes from the bloodstream towards target tissues, where they exert their effector function. Leukocyte extravasation is orchestrated by the combined action of cellular adhesion receptors and chemotactic factors, and involves radical morphological changes in both leukocytes and endothelial cells. Thus, it constitutes an active process for both cell types and promotes the rapid and efficient influx of leukocytes to inflammatory foci without compromising the integrity of the endothelial barrier. This article provides a review of leukocyte extravasation from both molecular and mechanical points of view, with a particular emphasis on the most recent findings on the topic. It includes a description of newly revealed steps in the adhesion cascade, such as slow rolling motion, intraluminal crawling and alternative pathways for transcellular migration, and discusses the functional role of novel adhesion receptors, the spatiotemporal organization of receptors at the plasma membrane and the signaling pathways that control different phases of the extravasation process.

Mesh:

Substances:

Year:  2009        PMID: 19406069     DOI: 10.1016/s1885-5857(09)71837-7

Source DB:  PubMed          Journal:  Rev Esp Cardiol        ISSN: 0300-8932            Impact factor:   4.753


  20 in total

1.  Selective induction of cell adhesion molecules by proinflammatory mediators in human cardiac microvascular endothelial cells in culture.

Authors:  Jun Yan; Adrian D Nunn; Regi Thomas
Journal:  Int J Clin Exp Med       Date:  2010-10-23

2.  Commentary: vedolizumab: a new mechanism of action for the treatment of ulcerative colitis.

Authors:  Stefan Schreiber
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-01

3.  Induction and maintenance therapy with vedolizumab, a novel biologic therapy for ulcerative colitis.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-01

Review 4.  Vedolizumab for the treatment of ulcerative colitis and Crohn's disease.

Authors:  Leon P McLean; Terez Shea-Donohue; Raymond K Cross
Journal:  Immunotherapy       Date:  2012-09       Impact factor: 4.196

Review 5.  Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease.

Authors:  Leon P McLean; Raymond K Cross
Journal:  Expert Opin Investig Drugs       Date:  2016       Impact factor: 6.206

Review 6.  Leukocyte Trafficking to the Small Intestine and Colon.

Authors:  Aida Habtezion; Linh P Nguyen; Husein Hadeiba; Eugene C Butcher
Journal:  Gastroenterology       Date:  2015-11-06       Impact factor: 22.682

7.  An ex vivo human placental vessel perfusion method to study mesenchymal stem/stromal cell migration.

Authors:  Balta Al-Sowayan; Rosemary J Keogh; Mohammed Abumaree; Harry M Georgiou; Bill Kalionis
Journal:  Stem Cell Investig       Date:  2019-01-02

8.  Implication for functions of the ectopic adipocyte copper amine oxidase (AOC3) from purified enzyme and cell-based kinetic studies.

Authors:  Sam H Shen; Diana L Wertz; Judith P Klinman
Journal:  PLoS One       Date:  2012-01-04       Impact factor: 3.240

9.  Peripheral leucocyte molecular indicators of inflammation and oxidative stress are altered in dairy cows with embryonic loss.

Authors:  Essa Dirandeh; M A Sayyar; Z Ansari-Pirsaraei; H Deldar; W W Thatcher
Journal:  Sci Rep       Date:  2021-06-17       Impact factor: 4.379

10.  Generation and characterization of feline arterial and venous endothelial cell lines for the study of the vascular endothelium.

Authors:  Dominique A J Olyslaegers; Lowiese M B Desmarets; Annelike Dedeurwaerder; Hannah L Dewerchin; Hans J Nauwynck
Journal:  BMC Vet Res       Date:  2013-08-29       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.